Deep-Tech Bio-Innovation: The Future of Health X
Focusing on the convergence of life sciences and advanced computation to address global health crises—moving beyond traditional therapies toward a holistic "Health X" framework that includes synthetic biology, predictive diagnostics, and AI-enhanced care.
Next‑Generation Therapeutics: Where Biochemistry Meets Intelligent Modeling: Investing in the intersection of organic chemistry, synthetic biology, and AI to create next-generation precision therapies and personalized medicine that scale globally.
Predictive & Proactive Diagnostics: Supporting deep-tech tools—from smartphone-based breath sensors and facial biomarkers in video feeds to epigenetic screening—that transition healthcare from reactive treatments to proactive using real-time monitoring.
Smarter Healthcare Workflows: Scaling innovative solutions that optimize the entire healthcare journey, including AI-driven drug discovery (AI acceleration for pharma) and digital platforms for specialized care management and clinical optimization workflows.
Host: Stina Wallmark, Investment Director (Voima Ventures)
About the company:
Voima Ventures is a Nordic & Baltic early‑stage deep tech fund backing science‑driven founders who are solving global problems through breakthrough technologies. While our roots are in deep tech across fields like advanced materials, quantum, and life sciences, we’ve also become a leading early investor in AI‑powered health innovation. Our portfolio includes companies building AI operating systems for oncology professionals, cutting‑edge epigenetic screening and drug‑discovery platforms and next‑generation diagnostics for neurological diseases such as Parkinson’s. As the host of this roundtable, we’re excited to bring together experts who are shaping how AI accelerates drug development and transforms the future of medicine.
Contributors to the session:
- Ann-Charlotte Beckman - CEO, Life Science Invest
- Maria Tell - COO and Investment Director, Segulah Medical
- Mia Ekdahl - General Partner, Björk Ventures
Welcome to sign up to participate in the discussion and/or listen in.
INVESTOR TICKET REQUIRED